Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

for
Triple Negative Breast Cancer
Location: New York NY, Nashville TN, Chicago IL, Aurora CO,
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Sex: All

Age: 18+

Code: NCT06908928

Phase 1, Recruiting

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

for
Head and Neck Squamous Cell Carcinoma,
Location: Shreveport LA
Sponsor: Pure Biologics S.A.

Sex: All

Age: 18+

Code: NCT06700070

Early Phase 1, Recruiting

Triple Negative Breast Cancer and Celecoxib. Pilot Study

for
Triple-Negative Breast Cancer
Location: Sherbrooke
Sponsor: UniversitƩ de Sherbrooke

Sex: Female

Age: 18+

Code: NCT07104266

Phase 2, Recruiting

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

for
TNBC, TNBC - Triple-Negative Breast Cancer,
Location: Los Angeles CA, Torrance CA
Sponsor: Cedars-Sinai Medical Center

Sex: All

Age: 18+

Code: NCT07017673

Phase 2, Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

for
Melanoma, Non-small Cell Lung Cancer,
Location: Fairfax VA, Pittsburgh PA, Grand Rapids MI, St Louis MO,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07115043

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: Atlanta GA
Sponsor: ProDa BioTech, LLC

Sex: All

Age: 18+

Code: NCT06460298

Phase 1, Phase 2, Recruiting

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

for
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer,
Location: Fairfax VA, Dallas TX
Sponsor: Hefei TG ImmunoPharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT05746897

Phase 1, Recruiting

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

for
Triple Negative Breast Cancer
Location: Portland OR, Los Angeles CA
Sponsor: Providence Health & Services

Sex: All

Age: 18+

Code: NCT06353997

Phase 2, Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.

Sex: All

Age: 18+

Code: NCT06451497

Phase 1, Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for
Triple Negative Breast Cancer
Location: Scarborough ME, South Weymouth MA, Boston MA,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase 3, Recruiting

Breast Cancer PSMA PET

for
Triple Negative Breast Cancer
Location: Iowa City IA
Sponsor: Ahmad Shariftabrizi

Sex: Female

Age: 18 - 70+

Code: NCT06586047

Early Phase 1, Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

for
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Location: Stony Brook NY, York PA, Washington DC DC,
Sponsor: Personalis Inc.

Sex: Female

Age: 18+

Code: NCT06230185

Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: Norfolk VA, Atlanta GA, Nashville TN, Germantown TN,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT06926920

Phase 1, Phase 2, Recruiting

The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction

for
Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases,
Location: Surrey, Vancouver
Sponsor: University of British Columbia

Sex: Female

Age: 21+

Code: NCT01427400

Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

for
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma,
Location: Duarte CA, Los Angeles CA, Stanford CA
Sponsor: Anusha Kalbasi

Sex: All

Age: 18 - 70+

Code: NCT04119024

Phase 1, Recruiting

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

for
Advanced Cancer, Gastric Cancer, Breast Cancer,
Location: Winston-Salem NC, Birmingham AL, Scottsdale AZ,
Sponsor: Minneamrita Therapeutics LLC

Sex: All

Age: 18+

Code: NCT03129139

Phase 1, Recruiting

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04771520

Phase 2, Recruiting

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Boston MA, Pittsburgh PA, Houston TX, Newport Beach CA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 12+

Code: NCT05372640

Phase 1, Recruiting

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

for
Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer,
Location: Fairfax VA, Plantation FL, Austin TX, San Antonio TX
Sponsor: Conjupro Biotherapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07424547

Phase 1, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for
Advanced Malignant Solid Neoplasm,
Location: Brewer ME, Augusta ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial